Preclinical Development of a Romidepsin Nanoparticle Demonstrates Superior Tolerability and Efficacy in Models of Human T-Cell Lymphoma and Large Granular Lymphocyte Leukemia
Ipsita Pal(University of Virginia), Owen A. O’Connor(Virginia Cancer Institute)
Cited by 2
Related Papers
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs
|Cancer Research|2008|222